Research Analysts Set Expectations for MAZE Q3 Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Investment analysts at HC Wainwright issued their Q3 2026 EPS estimates for Maze Therapeutics in a report released on Friday, November 7th. HC Wainwright analyst A. Ghosh expects that the company will earn ($0.74) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q4 2026 earnings at ($0.77) EPS.

Other equities analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a report on Wednesday, October 8th. BTIG Research boosted their price target on shares of Maze Therapeutics from $30.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. JPMorgan Chase & Co. lifted their price objective on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research note on Monday, September 29th. Finally, Wedbush upped their target price on shares of Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Maze Therapeutics presently has an average rating of “Buy” and an average price target of $37.00.

Maze Therapeutics Trading Down 3.5%

Shares of MAZE stock opened at $28.60 on Monday. The stock has a market capitalization of $1.25 billion and a price-to-earnings ratio of -1.37. Maze Therapeutics has a 12-month low of $6.71 and a 12-month high of $34.29. The stock’s 50-day moving average price is $25.85 and its 200-day moving average price is $17.31.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.08.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE raised its position in Maze Therapeutics by 33.6% in the 2nd quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock worth $71,000 after purchasing an additional 1,455 shares during the period. CWM LLC bought a new position in shares of Maze Therapeutics during the second quarter valued at approximately $28,000. New York State Common Retirement Fund purchased a new stake in shares of Maze Therapeutics in the first quarter worth approximately $25,000. Legal & General Group Plc lifted its stake in shares of Maze Therapeutics by 387.0% during the 2nd quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock worth $52,000 after acquiring an additional 3,371 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Maze Therapeutics by 80.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 7,890 shares of the company’s stock valued at $205,000 after acquiring an additional 3,524 shares during the period.

Insiders Place Their Bets

In other news, Director Richard H. Scheller sold 20,744 shares of the stock in a transaction on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a filing with the SEC, which is available at this link.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.